Press "Enter" to skip to content

US FDA warns Genetech for marketing dangerous stem cell products

The U.S. FDA has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice (CGTP) and current good manufacturing practice (CGMP) requirements

Original source:

Also Read:   Novo Nordisk appoints Vikrant Shrotriya as Managing Director, Novo Nordisk India